Table 1.
Results of IgG ELISA assay using controls and conjugates prepared in this study *.
| Antigen | Absorbance at 450 nm: Analyte | ||||
|---|---|---|---|---|---|
| a-PL | a-β2GPI | a-ssDNA | a-dsDNA | HNP (n = 10) | |
| CL | 1.97 | 0.90 | 0.90 | 0.63 | 0.45 |
| β2GPI | 0.75 | 1.01 | 0.60 | 0.32 | 0.22 |
| CL:β2GPI § | 0.98 | 0.80 | 0.55 | 0.61 | 0.52 |
| PT | 0.45 | 0.31 | 0.43 | 0.45 | 0.23 |
| BSA | 0.31 | 0.25 | 0.34 | 0.28 | 0.24 |
| PE azide | 1.03 | 0.91 | 0.80 | 0.54 | 0.33 |
| 5 (BSA-PE) | 1.44 | 0.56 | 1.44 | 1.21 | 0.43 |
| 6 (PT-PE) | 1.05 | 0.44 | 1.01 | 0.72 | 0.37 |
| 7 (β2GPI-PE) | 1.02 | 1.15 | 0.45 | 0.34 | 0.19 |
* a-PL, a-ssDNA and a-dsDNA = human plasma tested highly positive against phospholipids, single-stranded and double-stranded DNA, respectively; a-β2GPI = monoclonal Ab against β2GPI. HNP = human normal plasma; averaged absorbance for n patients is presented (Δ ± 0.20). § β2-Glycoprotein I (β2GPI; 0.001%) was added to CL under blocking conditions resulting in non-covalent binding. CL = CL, PT = prothrombin. Each sample was measured in the duplicate with resulting deviation in absorbance Δ ± 0.20.